



Durham Region Health Department FAX about...

For Health Care Professionals



Infant & High-Risk Children with RSV Prevention Program - Update

Infants born in hospital during the current RSV season (generally November until April) are provided Beyfortus[®] before discharge. Infants born outside the current RSV season, or outside the hospital setting, should receive Beyfortus[®] through their healthcare provider.

Beyfortus[®] - Infants and Children

Beyfortus[®], a monoclonal antibody (mAb) immunizing agent, is the preferred method for safeguarding infants. It is publicly funded for the following infants and children:

- Born in 2024 prior to the RSV season
- Born during the 2024/25 RSV season
- Up to 24 months of age and at-risk from severe RSV disease through the second RSV season with:
 - Chronic lung disease or hemodynamically significant congenital heart disease
 - Severe immunodeficiency or Down syndrome/Trisomy 21
 - Cystic fibrosis with respiratory involvement and/or growth delay
 - Neuromuscular disease impairing clearing of respiratory secretions
 - Severe congenital airway anomalies impairing the clearing of respiratory secretions

Beyfortus[®] Administration Guidelines for Infants and Children

Category	Weight	Dose	Timing
Infants born during the current RSV season	Less than 5 kg	50 mg in 0.5 mL (100 mg/mL)	Administered from birth
	Greater than or equal to 5 kg	100 mg in 1 mL (100 mg/mL)	Administered from birth
Infants born in 2024 before the current RSV season starts (up to 12 months of age)	Less than 5 kg	50 mg in 0.5 mL (100 mg/mL)	Shortly before start of the RSV season
	Greater than or equal to 5 kg	100 mg in 1 mL (100 mg/mL)	Shortly before start of the RSV season
Children over 12 months and up to 24 months of age and at continued high-risk from RSV infection	N/A	200 mg (two 1 mL injections of 100 mg/mL)*	Shortly before start of their second RSV season

*If a child weighs less than 10 kg entering their second RSV season, consideration can be given to administering a single dose of 100 mg at the clinical discretion of the provider.

905-668-2020 or 1-800-841-2729 | durham.ca/health

If you require this information in an accessible format, contact 1-800-841-2729.



Abrysvo™ - Pregnant Individuals

The Abrysvo™ vaccine is available for pregnant individuals from 32 to 36 weeks gestation, in consultation with a health care provider.

It is recommended to receive one product as a single dose (Abrysvo™ OR Beyfortus®), with Beyfortus® being the preferred method for safeguarding infants.

Ordering

To order Beyfortus® (both 50mg and 100mg doses) or Abrysvo™ use the online [RSV product order form \(durham.ca/hcp\)](#) see Respiratory illnesses, Respiratory Syncytial Virus (RSV) then Products and Order).

Currently, there is a limited supply of Beyfortus® 100mg. **Please ensure to administer doses currently in your vaccine fridge and order only what will be administered.**

For further information, including eligibility and Health Care Provider Fact Sheets, visit [durham.ca/hcp](#) (see Respiratory illnesses, Respiratory Syncytial Virus RSV) then Resources).

December 2, 2024

905-668-2020 or 1-800-841-2729 | [durham.ca/health](#)

If you require this information in an accessible format, contact 1-800-841-2729.

